---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-384430"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2026-09-08T12:17:06+00:00"
generated_at: "2026-09-08T12:20:13.913841+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veru pivots sabizabulin to daraxonrasib-resistant pancreatic cancer; drops cardiovascular program

## Summary
- Sabizabulin showed potent activity (IC50=18.2nM) in daraxonrasib-resistant KRAS pancreatic cancer cells; resistance index 0.25 vs 68 for daraxonrasib.
- Company plans Phase 2b trial in daraxonrasib-resistant metastatic pancreatic cancer; pre-IND meeting with FDA in Q4 2026.
- Veru will no longer explore sabizabulin for atherosclerotic cardiovascular disease inflammation; IP protection until 2043.
- Prior Phase 1b/2 data in 80 prostate cancer patients: median rPFS 11.4 months, ORR 20.7% at 63 mg daily dosing.
- Enobosarm obesity program on track: PLATEAU Phase 2b fully enrolled, interim analysis Q1 2027; Novo Nordisk supply deal.

## SEC filing metadata
- accession: 0001193125-26-384430
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2026-09-08T12:17:06+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312526384430/0001193125-26-384430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312526384430/d543118d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-384430
- JSON: https://secwatch.observer/filing/0001193125-26-384430.json
- Plain text: https://secwatch.observer/filing/0001193125-26-384430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.